Itoco (ITMC) Asset Impairment Charge : $0.00 Mil (TTM As of Sep. 2010)

View and export this data going back to 2009. Start your Free Trial

What is Itoco Asset Impairment Charge?

Itoco's Asset Impairment Charge for the three months ended in Sep. 2010 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2010 was $0.00 Mil.

Itoco Asset Impairment Charge Historical Data

The historical data trend for Itoco's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Itoco Asset Impairment Charge Chart

Itoco Annual Data

Trend

Dec08

Dec09

Asset Impairment Charge

Itoco Quarterly Data
	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10
Asset Impairment Charge	Get a 7-Day Free Trial						-	-	-	-	-

Itoco Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Itoco Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Itoco's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Itoco (ITMC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Itoco Inc (OTCPK:ITMC) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Liberty Street, Suite 880, Reno, NV, USA, 89501

Website

https://www.itoco.net

Itoco Inc is focused on developing and bringing biotech products to the market via co-development and joint venture arrangements with various companies. The company is currently examining various technologies that seek to control and/or identify bio-contaminants such as viruses and bacteria.